Plasma-derived therapies company Kedrion Biopharma announced on Tuesday that it will be honoured by Premier Inc, a technology-driven healthcare improvement company, during the annual Supplier Innovation Celebration at its 2026 Breakthroughs Conference and Exhibition.
The Innovation Celebration aims to recognise groundbreaking healthcare technologies launched throughout the year and highlight how these products help improve the health of communities.
Kedrion's QIVIGY was approved by the US Food and Drug Administration (FDA) in 2025 for the treatment of adults with primary humoral immunodeficiency (PI). It is also being studied across additional patient populations and indications.
BeOne Medicines wins FDA Priority Review for BRUKINSA combination in first-line mantle cell lymphoma
United Therapeutics eliminates Pfizer royalty obligations on ralinepag for USD525m
Pentixapharm advances preparationsfor Phase 3 PANDA study
StimLabs launches DermaForm collagen scaffold particulate device
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Vivesto secures US orphan drug designation for Cantrixil in acute myeloid leukemia
Lupin's Amifampridine Tablets approved by US FDA
Roche wins FDA clearance for customisable respiratory pathogen test
INOVIO's VOCERYQ receives US FDA accelerated approval to reduce surgery frequency in adults with RRP
Immunome secures EMA validation of varegacestat application for desmoid tumors
FDA approves Sun Pharma's ILUMYA for psoriatic arthritis
Celularity and Vesalius sign exclusive US peptide manufacturing agreement
Daiichi Sankyo secures EMA validation for two triple-combination cholesterol therapies
TME Pharma signs exclusive negotiation agreement with Japan's TMS for NOX-A12 rights